NCT04332588View on ClinicalTrials.gov

Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI

PHASE1RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 25, 2022

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
HER2-positive Breast Cancer
Interventions
DRUG

[18F]FMISO PET/MRI imaging

\[18F\]FMISO PET/MRI imaging

Trial Locations (1)

35249

RECRUITING

The University of Alabama at Birmingham, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER